Lipophilic drug delivery vehicle and methods of use thereof

Details Lipophilic drug delivery vehicle and methods of use thereof Lipophilic drug delivery vehicle and methods of use thereof

2004-02-13

2010-11-02

Kishore, Gollamudi S. (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S450000

Reexamination Certificate

active

07824709

ABSTRACT:
The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.

REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 4970144 (1990-11-01), Fareed et al.
patent: 5128318 (1992-07-01), Levine et al.
patent: 5490981 (1996-02-01), Chiknas
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5576016 (1996-11-01), Amselem et al.
patent: 5733761 (1998-03-01), Treco et al.
patent: 5744155 (1998-04-01), Friedman et al.
patent: 5746223 (1998-05-01), Williams
patent: 5874549 (1999-02-01), Hadley
patent: 5877302 (1999-03-01), Hanson et al.
patent: 5948441 (1999-09-01), Lenk et al.
patent: 6288040 (2001-09-01), Muller et al.
patent: 6458373 (2002-10-01), Lambert et al.
patent: 6489297 (2002-12-01), Burman et al.
patent: 6514523 (2003-02-01), Sparks
patent: 2001/0009670 (2001-07-01), Williams
patent: 2001/0016326 (2001-08-01), Giulian
patent: 2001/0016327 (2001-08-01), Giulian
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2001/0028895 (2001-10-01), Bisgaier et al.
patent: 2001/0031262 (2001-10-01), Caplan et al.
patent: 2001/0031740 (2001-10-01), Unger et al.
patent: 2001/0038845 (2001-11-01), Williams
patent: 2001/0038851 (2001-11-01), Allen et al.
patent: 2001/0052136 (2001-12-01), Lee et al.
patent: 2002/0001612 (2002-01-01), Papahadjopoulos et al.
patent: 2002/0015941 (2002-02-01), Kim et al.
patent: 2002/0018806 (2002-02-01), Agrawal et al.
patent: 2002/0022053 (2002-02-01), Williams
patent: 2002/0035082 (2002-03-01), Grinstaff et al.
patent: 2002/0035217 (2002-03-01), Uhrich
patent: 2002/0041894 (2002-04-01), Williams
patent: 2002/0048746 (2002-04-01), Lynch et al.
patent: 2002/0051813 (2002-05-01), Boni et al.
patent: 2002/0068070 (2002-06-01), Sasaki et al.
patent: 2002/0071862 (2002-06-01), Williams
patent: 2002/0156007 (2002-10-01), Graversen et al.
patent: 2004/0053384 (2004-03-01), Sligar et al.
patent: 0 277 849 (1988-08-01), None
patent: 0 277 849 (1988-08-01), None
patent: 2001-500886 (2001-01-01), None
patent: WO 96/25942 (1996-08-01), None
patent: WO-02/10501 (2002-02-01), None
patent: WO 02/40501 (2002-02-01), None
patent: WO 2004/050062 (2004-06-01), None
patent: WO-2004/073684 (2004-09-01), None
patent: WO-2004/073684 (2004-09-01), None
patent: WO-2005/039534 (2005-05-01), None
Vasanthy et al. Biochimia et Biophysics acta 1483 (2000)15-36.
Timothy et al. I and II protein science 2003 and Iangmuir 2000, 16.
International Journal of Pharmaceutics 117 ( 1995) 159-163. Egg and soya phospholipids—sonication and dialysis: A study on liposome characterization.
Anonymous. (1991). “Methods and Materials: Amplification of Nucleic Acid Sequences: The Choices Multiply,”The Journal of NIH Research3(2):81-94.
Arnheim, N. et al. (1990). “Polymerase Chain Reaction,”Chemical and Engineering News68(40):36-47.
Beckstead, J.A. et al. (2003). “Structure-Function Studies of Human Apolipoprotein A-V: A Regulator of Plasma Lipid Homeostasis,”Biochemistry42(31):9416-9423.
Beckstead, J.A. et al. (2005). “Combined N- and C-Terminal Truncation of Human Apolipoprotein A-I Yields a Folded, Functional Central Domain,”Biochemistry44(11):4591-4599.
Bielicki, J.K. et al. (2002). “Apolipoprotein A-IMilanoand Apolipoprotein A-IParisExhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I,”Biochemistry41(6):2089-2096.
Brushia, R.J. et al. (2001). “Baculovirus-Mediated Expression and Purification of Human Serum Paraoxonase 1A,”Journal of Lipid Research42:951-958.
Cheng, L. et al. (May 1993). “In Vivo Promoter Activity and Transgene Expression in Mammalian Somatic Tissues Evaluated by Using Particle Bombardment,”Proc. Natl. Acad. Sci. USA90:4455-4459.
Dettloff, M. et al. (2001). “An N-Terminal Three-Helix Fragment of the Exchangeable Insect Apolipoprotein Apolipophorin III Conserves the Lipid Binding Properties of Wild-Type Protein,”Biochemistry40(10):3150-3157.
Dettloff, M. et al. (2002). “Differential Lipid Binding of Truncation Mutants ofGalleria mellonellaApolipophorin III,”Biochemistry41(30):9688-9695.
Fisher, C.A. et al. (1999). “Lipid Binding-Induced Conformational Changes in the N-Terminal Domain of Human Apolipoprotein E,”Journal of Lipid Research40:93-99.
Fisher, C.A. et al. (Oct. 27, 2000). “The Lipid-Associated Conformation of the Low Density Lipoprotein Receptor Binding Domain of Human Apolipoprotein E,”The Journal of Biological Chemistry275(43):33601-33606.
Forte, T.M. et al. (1999). “Targeted Disruption of the Murine Lecithin:Cholesterol Acyltransferase Gene is Associated with Reductions in Plasma Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities but not in Apolipoprotein J Concentration,”Journal of Lipid Research40:1276-1283.
Forte, T.M. et al. (2002). “Altered Activities of Anti-Atherogenic Enzymes LCAT, Paraoxonase, and Platelet-Activating Factor Acetylhydrolase in Atherosclerosis-Susceptible Mice,”Journal of Lipid Research43:477-485.
Guatelli, J.C. et al. (Mar. 1990). “Isothermal, In Vitro Amplification of Nucleic Acids by a Multienzyme Reaction Modeled After Retroviral Replication,”Proc. Natl. Acad. Sci. USA87:1874-1878.
International Search Report mailed on Dec. 28, 2004, for PCT Patent Application No. PCT/US2004/025412 filed Sep. 2, 2004, 3 pages.
Janoff, A.S. et al. (Aug. 1988). “Unusual Lipid Structures Selelctively Reduce the Toxicity of Amphotericin B,”Proc. Natl. Acad. Sci. USA85:6122-6126.
Jonas, A. (1986). “Reconsitution of High-Density Lipoproteins,” Chapter 32 inMethods in Enzymology128:553-582.
Kiss, R.S. et al. (1993). “Physical Properties of Apolipoprotein A-I from the Chicken,Gallus domesticus,” Biochemistry32(31):7872-7878.
Kiss, R.S. et al. (1998). “Bacterial Expression and Characterization of Chicken Apolipoprotein A-I,”Protein Expresion and Purification12:353-360.
Kiss, R.S. et al. (1999). “Amphipathic α-Helix Bundle Organization of Lipid-Free Chicken Apolipoprotein A-I,”Biochemistry38(14):4327-4334.
Kiss, R.S. et al. (2001). “Functional Similarities of Human and Chicken Apolipoprotein A-I: Dependence on Secondary and Tertiary Rather than Primary Structure,”Biochimica et Biophysica Acta1531:251-259.
Kiss, R.S. et al. (Jun. 13, 2003). “Structure-Guided Protein Engineering Modulates Helix Bundle Exchangeable Apolipoprotein Properties,”The Journal of Biological Chemistry278(24):21952-21959.
Kwoh, D.Y. et al. (Feb. 1989). “Transcription-Based Amplification System and Detection of Amplified Human Immunodeficiency Virus Type 1 with a Bead-Based Sandwich Hybridization Format,”Proc. Natl. Acad. Sci. USA86:1173-1177.
Lagerstedt, J.O. et al. (Jan. 4, 2007). “EPR Spectroscopy of Site-Directed Spin Labels Reveals the Structural Heterogeneity in the N-Terminal Domain of APO-AI in Solution,”JBC Papers in Press, located at <http://www.jbc.org/cgi//doi/10.1074/jbc.M608717200>, 12 pages.
Liu, H. et al. (Jan. 1993). “Prevention of Phospholipase-C Induced Aggregation of Low Density Lipoprotein by Amphipathic Apolipoproteins,”FEBS316(1):27-33.
Martin, D.D.O. et al. (Jul. 21, 2006). “Apolipoprotein A-I Assumes a “Looped Belt” Conformation on Reconstituted High Density Lipoprotein,”The Journal of Biological Chemistry281(29):20418-20426.
Narang, S.A. et al. (1979). “Improved Phosphotriester Method For the Synthesis of Gene Fragments,” Chapter 6 inMethods in Enzymology, Academic Press, Inc., 68:90-99.
Narayanaswami, V. et al. (1994). “

Affiliated with

Also associated with

Rating

Lipophilic drug delivery vehicle and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipophilic drug delivery vehicle and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipophilic drug delivery vehicle and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4199695